While reporting financial results for the second quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) slashed its adjusted earnings and revenue growth guidance for the full-year 2023, primarily due to lower than expected sales of Revlimid, and to a lesser extent, Pomalyst.
from RTT - Earnings https://ift.tt/VPuUx9m
via IFTTT
No comments:
Post a Comment